Gianfranco Nazzi is VP at TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). They have made 11 open-market trades across 1 company since 2018, most recently 2021-03-04.
CIK 0001725018
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TEVA | 12,935 | $541K |
Shares reported on the most recent Form 4, priced at the 2021-03-08 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TEVA | SELL | 2021-03-04 | 2021-03-08 | $10.58 | $274K | +5.6% | +5.0% | -0.5% |
| TEVA | SELL · 10b5-1 | 2021-03-03 | 2021-03-04 | $10.88 | $15K | +5.2% | +9.6% | +0.6% |
| TEVA | SELL | 2021-03-01 | 2021-03-02 | $10.87 | $1.6M | -0.1% | +6.3% | -2.8% |
| TEVA | SELL | 2021-02-09 | 2021-02-11 | $12.72 | $550K | +0.2% | -1.3% | -9.1% |
| TEVA | SELL · 10b5-1 | 2020-03-17 | 2020-03-19 | $7.17 | $2K | +10.9% | +27.4% | +48.6% |
| TEVA | SELL · 10b5-1 | 2020-03-03 | 2020-03-05 | $11.77 | $6K | -30.8% | -10.8% | +21.4% |
| TEVA | SELL | 2020-02-10 | 2020-02-11 | $12.24 | $102K | -3.0% | -40.4% | -12.5% |
| TEVA | SELL | 2019-09-18 | 2019-09-20 | $7.82 | $8K | -4.8% | +11.2% | +36.0% |
| TEVA | SELL | 2019-03-18 | 2019-03-19 | $16.64 | $5K | -6.9% | -14.8% | -51.3% |
| TEVA | SELL | 2019-03-12 | 2019-03-14 | $15.69 | $5K | -3.7% | -11.9% | -47.3% |
| TEVA | SELL | 2019-03-04 | 2019-03-05 | $16.88 | $9K | +0.2% | -7.8% | -46.0% |
| TEVA | SELL | 2018-09-18 | 2018-09-20 | $23.69 | $33K | -11.9% | -14.2% | -34.2% |
| TEVA | SELL | 2018-03-19 | 2018-03-20 | $17.89 | $8K | -4.9% | +0.5% | +37.4% |
| TEVA | SELL | 2018-03-12 | 2018-03-14 | $19.50 | $9K | -9.3% | -3.0% | +29.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.